Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study

Authors :: Javier de la Serna
Martin Simkovic
Eric J. Avery
Cheng Quah
Iryna Kraychok
Daniel Lysák
Wei Liang
Tomas Kozak
Polina Kaplan
Andrzej Pluta
Priti Patel
Paolo Ghia
Sean Dolan
Malgorzata Wach
Wojciech Jurczak
Abraham Jacob
Phillip L. Campbell
Gerardo Musuraca
Jae Hoon Lee
Árpád Illés
Source :: Hematological Oncology. 37:86-87
Publication Year :: 2019
Publisher :: Wiley, 2019.

Subjects :: Bendamustine
Oncology
Cancer Research
medicine.medical_specialty
business.industry
Chronic lymphocytic leukemia
Hematology
General Medicine
medicine.disease
Internal medicine
Relapsed refractory
Medicine
Acalabrutinib
Rituximab
business
Idelalisib
medicine.drug

Full Text Access

Tools